NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration

The PNN as new target for NurExone’s ExoTherapy platform.

(A) Illustration of the extracellular Perineural network (PNN), highlighted in green. (B) Immunohistology of one protein in the PNN in differentiated neuronal culture demonstrate that the new treatment on human neuronal culture successfully degraded the PNN. (C) Quantification of one PNN building block protein that was successfully inhibited by the new treatment.

TORONTO and HAIFA, Israel, Nov. 29, 2023 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”) has recently unveiled laboratory tests of its secondary two proprietary sequences, representing a significant advancement in the treatment of spinal cord injuries. The biopharmaceutical company is using its biologically-guided exosome therapy ExoTherapy platform to expand its portfolio of products that will address spinal cord injuries and regeneration of neurons in other CNS indications. In the latest development, NurExone has developed two selective small inhibiting RNA sequences (siRNA) that target and inhibit proteins within the Peri-Neural Network (PNN) complex (Fig. 1A). The breakthrough sequences, detailed in a patent application held by the Company, are built upon a scientifically validated strategy for enhanced neuronal regeneration via inhibition of the PNN complex. The Company believes that its innovative approach, using the Company’s ExoTherapy platform to deliver these RNA sequences, will overcome limitations of previous methods. This marks a potential for two new products in the Company’s portfolio. The promise of the Company’s new sequences is evident in Figures 1B-1C, where PNN is notably reduced post-treatment. ExoPTEN, the Company’s first product under development, employs a distinct mechanism of action while sharing the same exosome-based drug delivery system. ExoPTEN has progressed to rat models, displaying regenerative properties and restoration of motor function, with human trials anticipated in the foreseeable future. Dr. Nisim Perets, inventor of the new approach, comments, “Inhibiting the proteins responsible for constructing the PNN scaffolding may restore the inherent neuro-regenerative potential humans are born with. This could be a game-changer in the treatment of spinal cord injury.” Dr. Lior Shaltiel, CEO of NurExone, adds, “Our scientific advancements and developments with the ExoTherapy platform are progressing rapidly, and the diversity of molecules in our arsenal will broaden our capacity to address neurological illnesses.” Figure 1: (A) Illustration of the extracellular Perineural network (PNN), highlighted in green. (B) Immunohistology of one protein in the PNN in differentiated neuronal culture demonstrate that the new treatment on human neuronal culture successfully degraded the PNN.(C) Quantification of one PNN building block protein that was successfully inhibited by the new treatment. About NurExone Biologic Inc. NurExone Biologic Inc. is a TSXV listed pharmaceutical company that is developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries. ExoTherapy was conceptually demonstrated in animal studies at the Technion, Israel Institute of Technology. NurExone is translating the treatment to humans, and the company holds an exclusive worldwide license from the Technion and Tel Aviv University for the development and commercialization of the technology. For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube. For more information, please contact: Dr. Lior ShaltielChief Executive Officer and DirectorPhone: +972-52-4803034Email: [email protected] Thesis Capital Inc.Investment Relation – CanadaPhone: +1 905-347-5569Email: [email protected] Dr. Eva ReuterInvestment Relation – GermanyPhone: +49-69-1532-5857Email: [email protected] FORWARD-LOOKING STATEMENTS This press release contains certain “forward-looking statements”, that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to the Company’s ExoTherapy drug, ExoPTEN. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including our ability to retain key personnel, our ability to continue investing in research and development, our ability to secure available funding and to continue as a going concern, the general business and economic conditions of the industries and countries in which we operate, our ability to execute on our business strategy, that there will be certain amount of demand for the Company’s potential product, inflation will remain stable, and that the results of our studies reflect results that can be extrapolated. Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the Company’s early stage of development, lack of revenues to date, government regulation, market acceptance for its products, rapid technological change, dependence on key personnel, protection of the Company’s intellectual property, dependence on the Company’s strategic partners and the risks discussed under the heading “Risk Factors” on pages 29 to 36 of the Company’s Annual Information Form dated March 30, 2023, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d1febbe6-921b-431a-b844-a814be12e06b